-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2019-07-15
Values as of: 2019-07-15
The investment seeks daily investment results, before fees and expenses, of 200% of the performance of the Dynamic Pharmaceutical Intellidex Index. The fund, under normal circumstances, creates long positions by investing at least 80% of its assets in the securities that comprise the Dynamic Pharmaceutical Intellidex Index and/or financial instruments that provide leveraged and unleveraged exposure to the index. The index consists of common shares of U.S. pharmaceutical companies. These companies are principally engaged in research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Company Website : http://www.direxioninvestments.com/
Currency: USD
Country : USA
Inception Date: 15/11/2017
Primary Benchmark: Dynamic Pharmaceutical Intellidex USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 6.74%
Management Expense Ratio: 0.98 %
N/A
N/A
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| SOJE | SOJE | 0.00 % |
+0.04 (+0.21%) |
USD 65.72B |
| JEPI | JPMorgan Equity Premium Income.. | 0.00 % |
-0.11 (-0.20%) |
USD 32.78B |
| LCR | Leuthold Core ETF | 0.00 % |
-0.09 (-0.27%) |
USD 32.52B |
| DTB | DTB | 0.00 % |
-0.12 (-0.63%) |
USD 26.58B |
| DFAC | Dimensional U.S. Core Equity 2.. | 0.00 % |
-0.03 (-0.10%) |
USD 26.11B |
| JPST | JPMorgan Ultra-Short Income ET.. | 0.00 % |
N/A |
USD 22.47B |
| SGOV | iShares® 0-3 Month Treasury B.. | 0.00 % |
+0.03 (+0.03%) |
USD 18.58B |
| TSPA | T. Rowe Price US Equity Resear.. | 0.00 % |
-0.07 (-0.22%) |
USD 16.23B |
| DFUV | Dimensional US Marketwide Valu.. | 0.00 % |
+0.04 (+0.10%) |
USD 10.15B |
| AVUV | Avantis® U.S. Small Cap Value.. | 0.00 % |
+0.02 (+0.02%) |
USD 10.05B |
N/A
| Market Performance vs. Industry/Classification (Others) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -22.35% | 4% | F | 6% | D- | ||
| Dividend Return | 0.37% | 9% | A- | 6% | D- | ||
| Total Return | -21.98% | 4% | F | 6% | D- | ||
| Trailing 12 Months | |||||||
| Capital Gain | -50.00% | 1% | F | 5% | F | ||
| Dividend Return | 0.67% | 13% | F | 9% | A- | ||
| Total Return | -49.33% | 1% | F | 5% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | 100% | F | 100% | F | ||
| Dividend Return | 2,874.50% | 100% | F | 100% | F | ||
| Total Return | N/A | 100% | F | 100% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 75,496.47% | 100% | F | 100% | F | ||
| Dividend Return | 75,496.63% | 100% | F | 100% | F | ||
| Total Return | 0.16% | 22% | F | 5% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | N/A | 1% | F | N/A | F | ||
| Risk Adjusted Return | 57.31% | 74% | C | 77% | C+ | ||
| Market Capitalization | 1.08M | 22% | F | 9% | A- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The company had positive total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
